Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1991 Sep;64(3):428–436. doi: 10.1038/bjc.1991.327

Nucleoside salvage and resistance to antimetabolite anticancer agents.

M Fox 1, J M Boyle 1, A R Kinsella 1
PMCID: PMC1977642  PMID: 1911182

Full text

PDF
428

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Aronow B., Allen K., Patrick J., Ullman B. Altered nucleoside transporters in mammalian cells selected for resistance to the physiological effects of inhibitors of nucleoside transport. J Biol Chem. 1985 May 25;260(10):6226–6233. [PubMed] [Google Scholar]
  2. Barton J. W., Hart I. M., Patterson D. Mapping of a locus correcting lack of phosphoribosylaminoimidazole carboxylase activity in Chinese hamster ovary cell Ade-D mutants to human chromosome 4. Genomics. 1991 Feb;9(2):314–321. doi: 10.1016/0888-7543(91)90259-h. [DOI] [PubMed] [Google Scholar]
  3. Beck J., Ullman B. Expression of a novel high affinity purine base transport system in mutant mouse S49 cells does not require a functional nucleoside transporter. Adv Exp Med Biol. 1989;253B:525–532. doi: 10.1007/978-1-4684-5676-9_78. [DOI] [PubMed] [Google Scholar]
  4. Belt J. A., Noel L. D. Isolation and characterization of a mutant of L1210 murine leukemia deficient in nitrobenzylthioinosine-insensitive nucleoside transport. J Biol Chem. 1988 Sep 25;263(27):13819–13822. [PubMed] [Google Scholar]
  5. Bhalla K., Grant S. Effect of deoxycytidine on the in vitro response of human leukemia cells to inhibitors of de novo pyrimidine biosynthesis. Cancer Chemother Pharmacol. 1987;19(3):226–232. doi: 10.1007/BF00252977. [DOI] [PubMed] [Google Scholar]
  6. Bontemps F., Vincent M. F., Van den Bergh F., van Waeg G., Van den Berghe G. Stimulation by glycerate 2,3-bisphosphate: a common property of cytosolic IMP-GMP 5'-nucleotidase in rat and human tissues. Biochim Biophys Acta. 1989 Jul 27;997(1-2):131–134. doi: 10.1016/0167-4838(89)90144-1. [DOI] [PubMed] [Google Scholar]
  7. Boyle J. M., Hey Y., Fox M. Nucleotide ectoenzyme activities of human and Chinese hamster fibroblasts in tissue culture. Biochem Genet. 1989 Dec;27(11-12):655–671. doi: 10.1007/BF02396058. [DOI] [PubMed] [Google Scholar]
  8. Bronstein A. D., Leleiko N. S., Munro H. N. RNA synthesis by villus and crypt cell nuclei of rat intestinal mucosa. Biochim Biophys Acta. 1983 Apr 15;739(3):334–343. doi: 10.1016/0167-4781(83)90109-4. [DOI] [PubMed] [Google Scholar]
  9. Budd G. T., Jayaraj A., Grabowski D., Adelstein D., Bauer L., Boyett J., Bukowski R., Murthy S., Weick J. Phase I trial of dipyridamole with 5-fluorouracil and folinic acid. Cancer Res. 1990 Nov 15;50(22):7206–7211. [PubMed] [Google Scholar]
  10. Bökkerink J. P., Bakker M. A., Hulscher T. W., De Abreu R. A., Schretlen E. D. Purine de novo synthesis as the basis of synergism of methotrexate and 6-mercaptopurine in human malignant lymphoblasts of different lineages. Biochem Pharmacol. 1988 Jun 15;37(12):2321–2327. doi: 10.1016/0006-2952(88)90358-9. [DOI] [PubMed] [Google Scholar]
  11. Cabral S., Leis S., Bover L., Nembrot M., Mordoh J. Dipyridamole inhibits reversion by thymidine of methotrexate effect and increases drug uptake in Sarcoma 180 cells. Proc Natl Acad Sci U S A. 1984 May;81(10):3200–3203. doi: 10.1073/pnas.81.10.3200. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Cadman E., Benz C. Uridine and cytidine metabolism following inhibition of de novo pyrimidine synthesis by pyrazofurin. Biochim Biophys Acta. 1980 Oct 17;609(3):372–382. doi: 10.1016/0005-2787(80)90111-2. [DOI] [PubMed] [Google Scholar]
  13. Camici M., Tozzi M. G., Allegrini S., Del Corso A., Sanfilippo O., Daidone M. G., De Marco C., Ipata P. L. Purine salvage enzyme activities in normal and neoplastic human tissues. Cancer Biochem Biophys. 1990 Jul;11(3):201–209. [PubMed] [Google Scholar]
  14. Cillo C., Ling V., Hill R. P. Drug resistance in KHT fibrosarcoma cell lines with different metastatic ability. Int J Cancer. 1989 Jan 15;43(1):107–111. doi: 10.1002/ijc.2910430121. [DOI] [PubMed] [Google Scholar]
  15. Cohen A., Leung C., Thompson E. Characterization of mouse lymphoma cells with altered nucleoside transport. J Cell Physiol. 1985 Jun;123(3):431–434. doi: 10.1002/jcp.1041230320. [DOI] [PubMed] [Google Scholar]
  16. Curtin N. J., Harris A. L. Potentiation of quinazoline antifolate (CB3717) toxicity by dipyridamole in human lung carcinoma, A549, cells. Biochem Pharmacol. 1988 Jun 1;37(11):2113–2120. doi: 10.1016/0006-2952(88)90568-0. [DOI] [PubMed] [Google Scholar]
  17. Deuchars K. L., Ling V. P-glycoprotein and multidrug resistance in cancer chemotherapy. Semin Oncol. 1989 Apr;16(2):156–165. [PubMed] [Google Scholar]
  18. Doerfler W. DNA methylation and gene activity. Annu Rev Biochem. 1983;52:93–124. doi: 10.1146/annurev.bi.52.070183.000521. [DOI] [PubMed] [Google Scholar]
  19. Dutrillaux B., Muleris M. Induction of increased salvage pathways of nucleotide synthesis by dosage effect due to chromosome imbalances may be fundamental in carcinogenesis: the example of colorectal carcinoma. Ann Genet. 1986;29(1):11–15. [PubMed] [Google Scholar]
  20. Feinberg A. P., Vogelstein B. Hypomethylation distinguishes genes of some human cancers from their normal counterparts. Nature. 1983 Jan 6;301(5895):89–92. doi: 10.1038/301089a0. [DOI] [PubMed] [Google Scholar]
  21. Fischer P. H., Pamukcu R., Bittner G., Willson J. K. Enhancement of the sensitivity of human colon cancer cells to growth inhibition by acivicin achieved through inhibition of nucleic acid precursor salvage by dipyridamole. Cancer Res. 1984 Aug;44(8):3355–3359. [PubMed] [Google Scholar]
  22. FitzGerald G. A. Dipyridamole. N Engl J Med. 1987 May 14;316(20):1247–1257. doi: 10.1056/NEJM198705143162005. [DOI] [PubMed] [Google Scholar]
  23. Fox M., Hodgkiss R. J. Mechanism of cytotoxic action of azaguanine and thioguanine in wild-type V79 cell lines and their relative efficiency in selection of structural gene mutants. Mutat Res. 1981 Jan;80(1):165–185. doi: 10.1016/0027-5107(81)90186-x. [DOI] [PubMed] [Google Scholar]
  24. Fox M., Roberts J. J. Drug resistance and DNA repair. Cancer Metastasis Rev. 1987;6(3):261–281. doi: 10.1007/BF00144267. [DOI] [PubMed] [Google Scholar]
  25. Galabov A. S., Mastikova M. Dipyridamole is an interferon inducer. Acta Virol. 1982 May;26(3):137–147. [PubMed] [Google Scholar]
  26. Gordon J. L. Extracellular ATP: effects, sources and fate. Biochem J. 1986 Jan 15;233(2):309–319. doi: 10.1042/bj2330309. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Grem J. L., Fischer P. H. Augmentation of 5-fluorouracil cytotoxicity in human colon cancer cells by dipyridamole. Cancer Res. 1985 Jul;45(7):2967–2972. [PubMed] [Google Scholar]
  28. Gutensohn W., Rieger J. Ectoenzymes of nucleotide metabolism on human lymphoid cells. Adv Exp Med Biol. 1986;195(Pt B):459–462. doi: 10.1007/978-1-4684-1248-2_71. [DOI] [PubMed] [Google Scholar]
  29. Gutensohn W., Thiel E., Buschette S. Ecto-5'-nucleotidase as a leukemia marker. Adv Exp Med Biol. 1984;165(Pt B):249–253. doi: 10.1007/978-1-4757-0390-0_48. [DOI] [PubMed] [Google Scholar]
  30. Howell S. B., Hom D. K., Sanga R., Vick J. S., Chan T. C. Dipyridamole enhancement of etoposide sensitivity. Cancer Res. 1989 Aug 1;49(15):4147–4153. [PubMed] [Google Scholar]
  31. Howell S. B., Hom D., Sanga R., Vick J. S., Abramson I. S. Comparison of the synergistic potentiation of etoposide, doxorubicin, and vinblastine cytotoxicity by dipyridamole. Cancer Res. 1989 Jun 15;49(12):3178–3183. [PubMed] [Google Scholar]
  32. Jakobs E. S., Paterson A. R. Sodium-dependent, concentrative nucleoside transport in cultured intestinal epithelial cells. Biochem Biophys Res Commun. 1986 Nov 14;140(3):1028–1035. doi: 10.1016/0006-291x(86)90738-2. [DOI] [PubMed] [Google Scholar]
  33. Jarvis S. M. Characterization of sodium-dependent nucleoside transport in rabbit intestinal brush-border membrane vesicles. Biochim Biophys Acta. 1989 Feb 13;979(1):132–138. doi: 10.1016/0005-2736(89)90533-6. [DOI] [PubMed] [Google Scholar]
  34. Jarvis S. M. Uniport carriers for metabolites. Curr Opin Cell Biol. 1989 Aug;1(4):721–728. doi: 10.1016/0955-0674(89)90040-9. [DOI] [PubMed] [Google Scholar]
  35. Jayaram H. N., Cooney D. A., Vistica D. T., Kariya S., Johnson R. K. Mechanisms of sensitivity or resistance of murine tumors to N-(phosphonacetyl)-L-aspartate (PALA). Cancer Treat Rep. 1979 Aug;63(8):1291–1302. [PubMed] [Google Scholar]
  36. Johnson R. K. Reversal of toxicity and antitumor activity of N-(phosphonacetyl)-L-aspartate by uridine or carbamyl-DL-asparate in vivo. Biochem Pharmacol. 1977 Jan 1;26(1):81–84. doi: 10.1016/0006-2952(77)90137-x. [DOI] [PubMed] [Google Scholar]
  37. Kaplinsky C., Yeger H., Estrov Z., Barankiewicz J., Pawlin G., Freedman M. H., Cohen A. Selective protection of tubercidin toxicity by nitrobenzyl thioinosine in normal tissues but not in human neuroblastoma cells. Cancer Chemother Pharmacol. 1986;17(3):264–268. doi: 10.1007/BF00256696. [DOI] [PubMed] [Google Scholar]
  38. Karle J. M., Anderson L. W., Cysyk R. L. Effect of plasma concentrations of uridine on pyrimidine biosynthesis in cultured L1210 cells. J Biol Chem. 1984 Jan 10;259(1):67–72. [PubMed] [Google Scholar]
  39. Karle J. M., Anderson L. W., Erlichman C., Cysyk R. L. Serum uridine levels in patients receiving N-(phosphonacetyl)-L-aspartate. Cancer Res. 1980 Aug;40(8 Pt 1):2938–2940. [PubMed] [Google Scholar]
  40. Kensler T. W., Reck L. J., Cooney D. A. Therapeutic effects of acivicin and N-(phosphonacetyl)-L-aspartic acid in a biochemically designed trial against a N-(phosphonacetyl)-L-aspartic acid-resistant variant of the Lewis lung carcinoma. Cancer Res. 1981 Mar;41(3):905–909. [PubMed] [Google Scholar]
  41. Kessel D., Dodd D. C. Effects of persantin on several transport systems of murine leukemias. Biochim Biophys Acta. 1972 Oct 23;288(1):190–194. doi: 10.1016/0005-2736(72)90237-4. [DOI] [PubMed] [Google Scholar]
  42. Kinsella A. R., Fiszer-Maliszewska L., Mitchell E. L., Guo Y. P., Fox M., Scott D. Introduction of the activated N-ras oncogene into human fibroblasts by retroviral vector induces morphological transformation and tumorigenicity. Carcinogenesis. 1990 Oct;11(10):1803–1809. doi: 10.1093/carcin/11.10.1803. [DOI] [PubMed] [Google Scholar]
  43. Kinsella A. R., Fox M. Phenotypic resistance to methotrexate and N-phosphonacetyl L-aspartate is induced by treatment with 12-O-tetradecanoylphorbol-13-acetate (TPA). Int J Cancer. 1988 Jul 15;42(1):87–93. doi: 10.1002/ijc.2910420117. [DOI] [PubMed] [Google Scholar]
  44. Kinsella A. R., Haran M. S. Decreasing sensitivity to cytotoxic agents parallels increasing tumorigenicity in human fibroblasts. Cancer Res. 1991 Apr 1;51(7):1855–1859. [PubMed] [Google Scholar]
  45. Kohn K. W., Pommier Y., Kerrigan D., Markovits J., Covey J. M. Topoisomerase II as a target of anticancer drug action in mammalian cells. NCI Monogr. 1987;(4):61–71. [PubMed] [Google Scholar]
  46. Kusumoto H., Maehara Y., Anai H., Kusumoto T., Sugimachi K. Potentiation of adriamycin cytotoxicity by dipyridamole against HeLa cells in vitro and sarcoma 180 cells in vivo. Cancer Res. 1988 Mar 1;48(5):1208–1212. [PubMed] [Google Scholar]
  47. LAJTHA L. G., VANE J. R. Dependence of bone marrow cells on the liver for purine supply. Nature. 1958 Jul 19;182(4629):191–192. doi: 10.1038/182191a0. [DOI] [PubMed] [Google Scholar]
  48. Lai L. W., Hart I. M., Patterson D. A gene correcting the defect in the CHO mutant Ade -H, deficient in a branch point enzyme (adenylosuccinate synthetase) of de novo purine biosynthesis, is located on the long arm of chromosome 1. Genomics. 1991 Feb;9(2):322–328. doi: 10.1016/0888-7543(91)90260-l. [DOI] [PubMed] [Google Scholar]
  49. Le Hir M., Dubach U. C. Uphill transport of pyrimidine nucleosides in renal brush border vesicles. Pflugers Arch. 1985 Jul;404(3):238–243. doi: 10.1007/BF00581245. [DOI] [PubMed] [Google Scholar]
  50. LeLeiko N. S., Bronstein A. D., Baliga B. S., Munro H. N. De novo purine nucleotide synthesis in the rat small and large intestine: effect of dietary protein and purines. J Pediatr Gastroenterol Nutr. 1983 May;2(2):313–319. [PubMed] [Google Scholar]
  51. Lennard L., Lilleyman J. S. Are children with lymphoblastic leukaemia given enough 6-mercaptopurine? Lancet. 1987 Oct 3;2(8562):785–787. doi: 10.1016/s0140-6736(87)92511-6. [DOI] [PubMed] [Google Scholar]
  52. Lennard L., Lilleyman J. S. Variable mercaptopurine metabolism and treatment outcome in childhood lymphoblastic leukemia. J Clin Oncol. 1989 Dec;7(12):1816–1823. doi: 10.1200/JCO.1989.7.12.1816. [DOI] [PubMed] [Google Scholar]
  53. Lock L. F., Melton D. W., Caskey C. T., Martin G. R. Methylation of the mouse hprt gene differs on the active and inactive X chromosomes. Mol Cell Biol. 1986 Mar;6(3):914–924. doi: 10.1128/mcb.6.3.914. [DOI] [PMC free article] [PubMed] [Google Scholar]
  54. Loh E., Kufe D. W. Synergistic effects with inhibitors of de novo pyrimidine synthesis, acivicin, and N-(phosphonacetyl)-L-aspartic acid. Cancer Res. 1981 Sep;41(9 Pt 1):3419–3423. [PubMed] [Google Scholar]
  55. Lüthje J. Extracellular adenine compounds, red blood cells and haemostasis: facts and hypotheses. Blut. 1989 Oct;59(4):367–374. doi: 10.1007/BF00321207. [DOI] [PubMed] [Google Scholar]
  56. Mackinnon A. M., Deller D. J. Purine nucleotide biosynthesis in gastrointestinal mucosa. Biochim Biophys Acta. 1973 Aug 10;319(1):1–4. doi: 10.1016/0005-2787(73)90034-8. [DOI] [PubMed] [Google Scholar]
  57. McDonald J. A., Kelley W. N. Lesch-Nyhan syndrome: altered kinetic properties of mutant enzyme. Science. 1971 Feb 19;171(3972):689–691. doi: 10.1126/science.171.3972.689. [DOI] [PubMed] [Google Scholar]
  58. Meinkoth J., Killary A. M., Fournier R. E., Wahl G. M. Unstable and stable CAD gene amplification: importance of flanking sequences and nuclear environment in gene amplification. Mol Cell Biol. 1987 Apr;7(4):1415–1424. doi: 10.1128/mcb.7.4.1415. [DOI] [PMC free article] [PubMed] [Google Scholar]
  59. Moscow J. A., Cowan K. H. Multidrug resistance. J Natl Cancer Inst. 1988 Mar 2;80(1):14–20. doi: 10.1093/jnci/80.1.14. [DOI] [PubMed] [Google Scholar]
  60. Moscow J. A., Townsend A. J., Goldsmith M. E., Whang-Peng J., Vickers P. J., Poisson R., Legault-Poisson S., Myers C. E., Cowan K. H. Isolation of the human anionic glutathione S-transferase cDNA and the relation of its gene expression to estrogen-receptor content in primary breast cancer. Proc Natl Acad Sci U S A. 1988 Sep;85(17):6518–6522. doi: 10.1073/pnas.85.17.6518. [DOI] [PMC free article] [PubMed] [Google Scholar]
  61. Moyer J. D., Handschumacher R. E. Selective inhibition of pyrimidine synthesis and depletion of nucleotide pools by N-(phosphonacetyl)-L-aspartate. Cancer Res. 1979 Aug;39(8):3089–3094. [PubMed] [Google Scholar]
  62. Nalbantoglu J., Meuth M. DNA amplification--deletion in a spontaneous mutation of the hamster aprt locus: structure and sequence of the novel joint. Nucleic Acids Res. 1986 Nov 11;14(21):8361–8371. doi: 10.1093/nar/14.21.8361. [DOI] [PMC free article] [PubMed] [Google Scholar]
  63. Natsumeda Y., Ikegami T., Olah E., Weber G. Significance of purine salvage in circumventing the action of antimetabolites in rat hepatoma cells. Cancer Res. 1989 Jan 1;49(1):88–92. [PubMed] [Google Scholar]
  64. Natsumeda Y., Prajda N., Donohue J. P., Glover J. L., Weber G. Enzymic capacities of purine de Novo and salvage pathways for nucleotide synthesis in normal and neoplastic tissues. Cancer Res. 1984 Jun;44(6):2475–2479. [PubMed] [Google Scholar]
  65. Nelson J. A., Drake S. Potentiation of methotrexate toxicity by dipyridamole. Cancer Res. 1984 Jun;44(6):2493–2496. [PubMed] [Google Scholar]
  66. Otto E., McCord S., Tlsty T. D. Increased incidence of CAD gene amplification in tumorigenic rat lines as an indicator of genomic instability of neoplastic cells. J Biol Chem. 1989 Feb 25;264(6):3390–3396. [PubMed] [Google Scholar]
  67. Piafsky K. M., Borgå O. Plasma protein binding of basic drugs. II. Importance of alpha 1-acid glycoprotein for interindividual variation. Clin Pharmacol Ther. 1977 Nov;22(5 Pt 1):545–549. doi: 10.1002/cpt1977225part1545. [DOI] [PubMed] [Google Scholar]
  68. Pieters R., Huismans D. R., Veerman A. J. Are children with lymphoblastic leukaemia resistant to 6-mercaptopurine because of 5'-nucleotidase? Lancet. 1987 Dec 19;2(8573):1471–1471. doi: 10.1016/s0140-6736(87)91176-7. [DOI] [PubMed] [Google Scholar]
  69. Plagemann P. G., Behrens M. Inhibition of de novo pyrimidine nucleotide and DNA synthesis and growth of cultured Novikoff rat hepatoma cells and other cell lines by pyrazofurin (NSC 143095). Cancer Res. 1976 Oct;36(10):3807–3812. [PubMed] [Google Scholar]
  70. Plagemann P. G., Marz R., Wohlhueter R. M., Graff J. C., Zylka J. M. Facilitated transport of 6-mercaptopurine and 6-thioguanine and non-mediated permeation of 8-azaguanine in Novikoff rat hepatoma cells and relationship to intracellular phosphoribosylation. Biochim Biophys Acta. 1981 Sep 21;647(1):49–62. doi: 10.1016/0005-2736(81)90294-7. [DOI] [PubMed] [Google Scholar]
  71. Plagemann P. G., Woffendin C. Na+-dependent and -independent transport of uridine and its phosphorylation in mouse spleen cells. Biochim Biophys Acta. 1989 Jun 6;981(2):315–325. doi: 10.1016/0005-2736(89)90043-6. [DOI] [PubMed] [Google Scholar]
  72. Plagemann P. G., Wohlhueter R. M., Woffendin C. Nucleoside and nucleobase transport in animal cells. Biochim Biophys Acta. 1988 Oct 11;947(3):405–443. doi: 10.1016/0304-4157(88)90002-0. [DOI] [PubMed] [Google Scholar]
  73. Prus K. L., Averett D. R., Zimmerman T. P. Transport and metabolism of 9-beta-D-arabinofuranosylguanine in a human T-lymphoblastoid cell line: nitrobenzylthioinosine-sensitive and -insensitive influx. Cancer Res. 1990 Mar 15;50(6):1817–1821. [PubMed] [Google Scholar]
  74. Puchalski R. B., Fahl W. E. Expression of recombinant glutathione S-transferase pi, Ya, or Yb1 confers resistance to alkylating agents. Proc Natl Acad Sci U S A. 1990 Apr;87(7):2443–2447. doi: 10.1073/pnas.87.7.2443. [DOI] [PMC free article] [PubMed] [Google Scholar]
  75. Reid L. H., Gregg R. G., Smithies O., Koller B. H. Regulatory elements in the introns of the human HPRT gene are necessary for its expression in embryonic stem cells. Proc Natl Acad Sci U S A. 1990 Jun;87(11):4299–4303. doi: 10.1073/pnas.87.11.4299. [DOI] [PMC free article] [PubMed] [Google Scholar]
  76. Riggs A. D., Jones P. A. 5-methylcytosine, gene regulation, and cancer. Adv Cancer Res. 1983;40:1–30. doi: 10.1016/s0065-230x(08)60678-8. [DOI] [PubMed] [Google Scholar]
  77. Rose K. M. DNA topoisomerases as targets for chemotherapy. FASEB J. 1988 Jun;2(9):2474–2478. doi: 10.1096/fasebj.2.9.2836254. [DOI] [PubMed] [Google Scholar]
  78. Savaiano D. A., Clifford A. J. Adenine, the precursor of nucleic acids in intestinal cells unable to synthesize purines de novo. J Nutr. 1981 Oct;111(10):1816–1822. doi: 10.1093/jn/111.10.1816. [DOI] [PubMed] [Google Scholar]
  79. Scavennec J., Maraninchi D., Gastaut J. A., Carcassonne Y., Cailla H. L. Purine and pyrimidine ribonucleoside monophosphate patterns of peripheral blood and bone marrow cells in human acute leukemias. Cancer Res. 1982 Apr;42(4):1326–1330. [PubMed] [Google Scholar]
  80. Schimke R. T. Gene amplification, drug resistance, and cancer. Cancer Res. 1984 May;44(5):1735–1742. [PubMed] [Google Scholar]
  81. Schwenk M., Hegazy E., Lopez del Pino V. Uridine uptake by isolated intestinal epithelial cells of guinea pig. Biochim Biophys Acta. 1984 Dec 11;805(4):370–374. doi: 10.1016/0167-4889(84)90020-x. [DOI] [PubMed] [Google Scholar]
  82. Sinkeler S., Joosten E., Wevers R., Binkhorst R., Oei L. Skeletal muscle adenosine, inosine and hypoxanthine release following ischaemic forearm exercise in myoadenylate deaminase deficiency and McArdle's disease. Adv Exp Med Biol. 1986;195(Pt B):517–523. doi: 10.1007/978-1-4684-1248-2_80. [DOI] [PubMed] [Google Scholar]
  83. Sobrero A. F., Moir R. D., Bertino J. R., Handschumacher R. E. Defective facilitated diffusion of nucleosides, a primary mechanism of resistance to 5-fluoro-2'-deoxyuridine in the HCT-8 human carcinoma line. Cancer Res. 1985 Jul;45(7):3155–3160. [PubMed] [Google Scholar]
  84. Sowemimo-Coker S. O., Kovacs I. B., Pickles H., Hedges A., Turner P. Dipyridamole increases red cell deformability. Br J Clin Pharmacol. 1983 Oct;16(4):423–425. doi: 10.1111/j.1365-2125.1983.tb02188.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  85. Spychała J., Madrid-Marina V., Fox I. H. High Km soluble 5'-nucleotidase from human placenta. Properties and allosteric regulation by IMP and ATP. J Biol Chem. 1988 Dec 15;263(35):18759–18765. [PubMed] [Google Scholar]
  86. Szebeni J., Wahl S. M., Popovic M., Wahl L. M., Gartner S., Fine R. L., Skaleric U., Friedmann R. M., Weinstein J. N. Dipyridamole potentiates the inhibition by 3'-azido-3'-deoxythymidine and other dideoxynucleosides of human immunodeficiency virus replication in monocyte-macrophages. Proc Natl Acad Sci U S A. 1989 May;86(10):3842–3846. doi: 10.1073/pnas.86.10.3842. [DOI] [PMC free article] [PubMed] [Google Scholar]
  87. Thompson L. F. Ecto-5'-nucleotidase can use IMP to provide the total purine requirements of mitogen-stimulated human T cells and human B lymphoblasts. Adv Exp Med Biol. 1986;195(Pt B):467–473. doi: 10.1007/978-1-4684-1248-2_73. [DOI] [PubMed] [Google Scholar]
  88. Turner D. R., Morley A. A., Haliandros M., Kutlaca R., Sanderson B. J. In vivo somatic mutations in human lymphocytes frequently result from major gene alterations. Nature. 1985 May 23;315(6017):343–345. doi: 10.1038/315343a0. [DOI] [PubMed] [Google Scholar]
  89. Van Loon J. A., Weinshilboum R. M. Thiopurine methyltransferase biochemical genetics: human lymphocyte activity. Biochem Genet. 1982 Aug;20(7-8):637–658. doi: 10.1007/BF00483962. [DOI] [PubMed] [Google Scholar]
  90. Veerman A. J., Hogeman P. H., van Zantwijk C. H., Bezemer P. D. Prognostic value of 5'nucleotidase in acute lymphoblastic leukemia with the common-ALL phenotype. Leuk Res. 1985;9(10):1227–1229. doi: 10.1016/0145-2126(85)90149-3. [DOI] [PubMed] [Google Scholar]
  91. Verschueren H., Wildemauwe C., Van Larebeke N. Effects of dipyridamole (Persantin R) on morphology and motility of mouse embryo cells. Cell Biol Int Rep. 1983 Apr;7(4):263–270. doi: 10.1016/0309-1651(83)90060-7. [DOI] [PubMed] [Google Scholar]
  92. WILLIAMS A. M. Nucleic acid metabolism in leukemic human leukocytes. I. In vitro incorporation by leukocytes from chronic granulocytic leukemia. Cancer Res. 1962 Apr;23:314–321. [PubMed] [Google Scholar]
  93. Wahl G. M., Padgett R. A., Stark G. R. Gene amplification causes overproduction of the first three enzymes of UMP synthesis in N-(phosphonacetyl)-L-aspartate-resistant hamster cells. J Biol Chem. 1979 Sep 10;254(17):8679–8689. [PubMed] [Google Scholar]
  94. Walsh M. J., Sanchez-Pozo A., Leleiko N. S. A regulatory element is characterized by purine-mediated and cell-type-specific gene transcription. Mol Cell Biol. 1990 Aug;10(8):4356–4364. doi: 10.1128/mcb.10.8.4356. [DOI] [PMC free article] [PubMed] [Google Scholar]
  95. Weber G. Biochemical strategy of cancer cells and the design of chemotherapy: G. H. A. Clowes Memorial Lecture. Cancer Res. 1983 Aug;43(8):3466–3492. [PubMed] [Google Scholar]
  96. Weber G., Jayaram H. N., Lapis E., Natsumeda Y., Yamada Y., Yamaji Y., Tricot G. J., Hoffman R. Enzyme-pattern-targeted chemotherapy with tiazofurin and allopurinol in human leukemia. Adv Enzyme Regul. 1988;27:405–433. doi: 10.1016/0065-2571(88)90029-5. [DOI] [PubMed] [Google Scholar]
  97. Weinshilboum R. M., Sladek S. L. Mercaptopurine pharmacogenetics: monogenic inheritance of erythrocyte thiopurine methyltransferase activity. Am J Hum Genet. 1980 Sep;32(5):651–662. [PMC free article] [PubMed] [Google Scholar]
  98. Weisman G. A., Lustig K. D., Lane E., Huang N. N., Belzer I., Friedberg I. Growth inhibition of transformed mouse fibroblasts by adenine nucleotides occurs via generation of extracellular adenosine. J Biol Chem. 1988 Sep 5;263(25):12367–12372. [PubMed] [Google Scholar]
  99. Wohlhueter R. M., McIvor R. S., Plagemann P. G. Facilitated transport of uracil and 5-fluorouracil, and permeation of orotic acid into cultured mammalian cells. J Cell Physiol. 1980 Sep;104(3):309–319. doi: 10.1002/jcp.1041040305. [DOI] [PubMed] [Google Scholar]
  100. Wood A. W., Becker M. A., Seegmiller J. E. Purine nucleotide synthesis in lymphoblasts cultured from normal subjects and a patient with Lesch-Nyhan syndrome. Biochem Genet. 1973 Jul;9(3):261–274. doi: 10.1007/BF00485739. [DOI] [PubMed] [Google Scholar]
  101. Wright J. A., Smith H. S., Watt F. M., Hancock M. C., Hudson D. L., Stark G. R. DNA amplification is rare in normal human cells. Proc Natl Acad Sci U S A. 1990 Mar;87(5):1791–1795. doi: 10.1073/pnas.87.5.1791. [DOI] [PMC free article] [PubMed] [Google Scholar]
  102. Wung W. E., Howell S. B. Hypoxanthine concentrations in normal subjects and patients with solid tumors and leukemia. Cancer Res. 1984 Jul;44(7):3144–3148. [PubMed] [Google Scholar]
  103. Yen P. H., Mohandas T., Shapiro L. J. Stability of DNA methylation of the human hypoxanthine phosphoribosyltransferase gene. Somat Cell Mol Genet. 1986 Mar;12(2):153–161. doi: 10.1007/BF01560662. [DOI] [PubMed] [Google Scholar]
  104. Zieg J., Clayton C. E., Ardeshir F., Giulotto E., Swyryd E. A., Stark G. R. Properties of single-step mutants of Syrian hamster cell lines resistant to N-(phosphonacetyl)-L-aspartate. Mol Cell Biol. 1983 Nov;3(11):2089–2098. doi: 10.1128/mcb.3.11.2089. [DOI] [PMC free article] [PubMed] [Google Scholar]
  105. Zimm S., Ettinger L. J., Holcenberg J. S., Kamen B. A., Vietti T. J., Belasco J., Cogliano-Shutta N., Balis F., Lavi L. E., Collins J. M. Phase I and clinical pharmacological study of mercaptopurine administered as a prolonged intravenous infusion. Cancer Res. 1985 Apr;45(4):1869–1873. [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES